Is Maestro a surgical robot or a co-pilot?

Maestro is an ASSISTIVE laparoscopy co-pilot, NOT a replacement surgical robot per DEPLOY's surgical cluster framework. Maestro (assistive): augments surgeons within existing laparoscopic procedures; co-pilot integration with laparoscopic instrument manipulation; does NOT replace the surgeon's primary laparoscopic technique. Replacement-robotics (Intuitive da Vinci, CMR Versius, Medtronic Hugo, J&J Ottava): replaces direct-manipulation laparoscopy with teleoperated console-driven robotic surgery. Per DEPLOY's framework, the assistive-vs-replacement distinction is the load-bearing editorial throughline at the surgical-cluster commercial-model variance layer.

What's the difference between Maestro and da Vinci?

Surgical positioning. Maestro (assistive): augments surgeons within existing laparoscopic procedures; co-pilot integration with laparoscopic instrument manipulation; smaller-footprint OR integration; does NOT replace the surgeon's primary laparoscopic technique; FDA 510(k) K240598 cleared June 2024. Intuitive da Vinci (replacement-robotics): replaces direct-manipulation laparoscopy with teleoperated console-driven robotic surgery; surgeon at console drives the robotic arms; 11,395 da Vinci + 1,041 Ion systems installed-base. Per DEPLOY's surgical cluster framework, Maestro anchors the assistive-laparoscopy commercial-niche archetype; da Vinci anchors the market-leader installed-base replacement-robotics archetype.

How much does Moon Surgical Maestro cost?

Consumer-surface pricing forthcoming via Agent B's parallel surgical /price expansion per DEPLOY's surgical cluster framework. The /price page operates at honest-absence pending Agent B's parallel ship per cap-flag-as-trust-signal. Per DEPLOY's framework, surgical-platform pricing operates at hospital-system + surgical-services-network procurement tier rather than consumer retail; aggregator-quoted unit pricing without Moon Surgical primary-source confirmation operates outside DEPLOY's verification posture. Registry institutional depth available at Moon Surgical registry company + Maestro registry model.

Explainers Surgical robotics

What is Moon Surgical Maestro?

Q: Is Moon Surgical Maestro FDA-cleared?

Yes, FDA 510(k) K240598 cleared June 2024 per primary-source FDA database verification. Both K-number + clearance date operate at primary-source-anchored verification tier. Editorial-transparency: this anchor previously framed clearance as "December 2023 (specific K-number at cap-flag pending primary-source confirmation)"; primary-source FDA database research surfaces K240598 cleared June 2024 (corrected June 4, 2026 per Project C Anchor 2 framework-in-action narrative). The verified gating-event places Maestro at the verified-commercial-shipped tier within the cohort, distinct from US-pre-market surgical entrants (J&J Ottava De Novo submission January 2026 + Vicarious Surgical V1 SPAC-era distressed pre-market).

Moon Surgical Maestro is the Maestro Laparoscopy Co-Pilot, an FDA-cleared ASSISTIVE (NOT replacement) robotic system for laparoscopic procedures from Moon Surgical, a French-US dual-base company founded 2020. Per DEPLOY's surgical cluster framework: FDA 510(k) K240598 cleared June 2024 (primary-source FDA database verification). EDITORIAL DISTINCTION: assistive-laparoscopy positioning. Maestro augments surgeons within existing laparoscopic procedures rather than replacing them as full surgical platforms (Intuitive da Vinci, Medtronic Hugo, CMR Versius, J&J Ottava). Smaller-footprint OR integration + commercial-niche positioning. Per DEPLOY's surgical cluster framework, Maestro is the cohort's genuine shipped assistive-AI exemplar within the broader replacement-robotics cluster. Cohort positioning: assistive-laparoscopy commercial-niche archetype within the surgical cluster, extending the cluster's structural axes from FDA-clearance-posture (Wave 1) into clinical-domain + commercial-model variance (Wave 2).

French-US dual base (2020)

Moon Surgical founding + headquarters

FDA 510(k) K240598 (Jun 2024)

Verified-shipped commercial tier (K-number + clearance date primary-source-anchored)

ASSISTIVE (NOT replacement)

Co-pilot positioning vs replacement-robotics dominant cluster

Laparoscopy integration

Clinical-domain scope

Smaller-footprint OR integration

Commercial-niche positioning

Mid-2026

Snapshot date

FDA 510(k) K240598 cleared June 2024; verified-shipped commercial tier

Per DEPLOY's surgical cluster framework, Moon Surgical Maestro holds FDA 510(k) K240598 clearance dated June 2024 per primary-source FDA database verification. Both K-number + clearance date operate at primary-source-anchored verification tier. Editorial-transparency: this anchor previously framed clearance as "December 2023 (specific K-number at cap-flag pending primary-source confirmation)"; primary-source FDA database research surfaces K240598 cleared June 2024 (corrected June 4, 2026 per Project C Anchor 2 framework-in-action narrative). The June 2024 FDA clearance positions Maestro structurally distinct from US-pre-market surgical entrants: distinct from J&J Ottava (De Novo submission January 2026; "not authorized to be marketed") + Vicarious Surgical V1 (SPAC-era distressed pre-market). The verified gating-event (FDA 510(k) K240598 clearance) places Maestro at the verified-commercial-shipped tier within the cohort.

Moon Surgical Maestro: assistive-laparoscopy commercial-niche archetype

Moon Surgical Maestro is the Maestro Laparoscopy Co-Pilot, an FDA-cleared ASSISTIVE (NOT replacement) robotic system for laparoscopic procedures from Moon Surgical, a French-US dual-base company founded 2020. Per DEPLOY's surgical cluster framework, Maestro anchors the assistive-laparoscopy commercial-niche archetype within the surgical cluster, extending the cluster's structural axes from FDA-clearance-posture (Wave 1) into clinical-domain + commercial-model variance.

Moon Surgical: French-US dual base, founded 2020

Moon Surgical is a French-US dual-base surgical robotics company founded 2020. The French + US dual-headquartered structure positions Moon within the international + US surgical robotics industrial base layers; the founding cohort + leadership operates across French + US surgical-technology development infrastructure.

FDA 510(k) K240598 cleared June 2024

Per DEPLOY's surgical cluster framework, Moon Surgical Maestro holds FDA 510(k) K240598 clearance dated June 2024. The K240598 designation operates at primary-source FDA database verification per Agent A research; K-number + clearance date both verified at primary-source-anchored tier. Editorial-transparency note: this anchor previously framed clearance as "December 2023 (specific K-number at cap-flag pending primary-source confirmation)"; primary-source FDA database verification surfaces K240598 cleared June 2024 (corrected June 4, 2026). The framework-in-action correction is documented at Project C Anchor 2 narrative depth.

The June 2024 FDA clearance positions Maestro structurally distinct from US-pre-market surgical entrants: distinct from J&J Ottava (De Novo submission January 2026; "not authorized to be marketed") + Vicarious Surgical V1 (SPAC-era distressed pre-market). The verified gating-event (FDA 510(k) K240598 clearance) places Maestro at the verified-commercial-shipped tier within the cohort.

CRITICAL EDITORIAL DISTINCTION: ASSISTIVE (NOT replacement)

Per DEPLOY's surgical cluster framework, the Maestro positioning is ASSISTIVE (NOT replacement) for laparoscopic procedures. The assistive-vs-replacement distinction matters editorially at the cohort-architecture layer:

Maestro (assistive): augments surgeons within existing laparoscopic procedures; co-pilot integration with laparoscopic instrument manipulation; does NOT replace the surgeon's primary laparoscopic technique.
Replacement-robotics (Intuitive da Vinci, CMR Versius, Medtronic Hugo, J&J Ottava): replaces direct-manipulation laparoscopy with teleoperated console-driven robotic surgery; surgeon at console drives the robotic arms.

Per DEPLOY's framework, the assistive-vs-replacement distinction is the load-bearing editorial throughline at the surgical-cluster commercial-model variance layer: trade-press coverage that flattens Maestro into "another robotic surgical platform" operates outside the assistive-positioning verification scope. The assistive-laparoscopy commercial-niche archetype is structurally distinct from the dominant replacement-robotics cluster positioning.

Smaller-footprint OR integration

Per DEPLOY's surgical cluster framework, Maestro's assistive positioning enables smaller-footprint OR integration: the system integrates into existing laparoscopic procedure workflows rather than requiring dedicated robotic-surgery OR configuration. Per DEPLOY's framework, the smaller-footprint positioning is editorial signal at the deployment-friction layer: traditional replacement-robotics platforms (da Vinci, Versius, Hugo, Ottava) require substantial OR investment + dedicated procedure scheduling + training infrastructure; Maestro's assistive positioning operates at lower OR-investment + training tier.

Per cap-flag-as-trust-signal, specific commercial-deployment scale figures cap-flagged pending Moon-disclosed primary-source confirmation: aggregator-quoted deployment figures vs Moon Surgical-disclosed figures may vary; primary-source-anchored verification is load-bearing.

Cohort's genuine shipped assistive-AI exemplar

Per the existing surgical cluster framework intro, Moon Surgical operates as the cohort's autonomy-spectrum-genuine shipped surgical AI standout (ScoPilot autonomous-registration with Predetermined Change Control Plan). Maestro extends Moon Surgical's verified-shipped assistive-AI positioning into the laparoscopy co-pilot scope:

Autonomy spectrum: Maestro operates as assistive co-pilot within surgeon-directed laparoscopic procedures; NOT autonomous-tissue-manipulation; NOT teleoperated full-replacement.
FDA-cleared narrow autonomous functions within the assistive scope.

Per DEPLOY's framework, the assistive-AI + FDA-cleared posture is editorial signal at the cohort's autonomy-spectrum verification layer: Maestro represents verified-shipped commercial-surgical AI at the assistive integration tier (distinct from research-tier autonomous-tissue-manipulation that does NOT yet exist as a shipped product).

Cohort positioning: assistive-laparoscopy commercial-niche archetype

Per the surgical cluster framework, Moon Surgical Maestro anchors:

Assistive-laparoscopy commercial-niche archetype: assistive co-pilot positioning; smaller-footprint OR integration; commercial-niche scope distinct from replacement-robotics dominant cluster positioning.
FDA 510(k) K240598 cleared June 2024: verified-shipped commercial tier; verified gating-event distinct from pre-market entrants.
Moon Surgical French-US dual-base founded 2020: international + US surgical robotics industrial base.
Wave 2 expansion structural axis: clinical-domain + commercial-model variance extending cluster beyond Wave 1 FDA-clearance-posture coverage.

Contrast with cohort:

Intuitive da Vinci: market-leader installed-base; 11,395 da Vinci + 1,041 Ion systems; replacement-robotics monolithic architecture.
J&J Ottava: pre-market research-tier; De Novo submission January 2026; "not authorized to be marketed."
CMR Versius: international commercial soft-tissue; UK-headquartered modular architecture; US clearance state cap-flagged.

The Wave 2 expansion's structural point: Wave 1 covered general-laparoscopy variance across FDA-clearance states; Wave 2 extends into clinical-domain + commercial-model variance. Three structural axes now live on surgical cluster: FDA-clearance-posture (Wave 1) + clinical-domain (Wave 2) + commercial-model (Wave 2). Maestro anchors the commercial-model variance axis (assistive vs replacement); Versius anchors the clinical-domain + international-commercial axes.

Consumer pricing surface for Moon Surgical Maestro is forthcoming via Agent B's parallel surgical /price expansion; per cap-flag-as-trust-signal, the consumer-price-page is documented as forthcoming honest-absence pending Agent B's parallel ship. Registry institutional depth at Moon Surgical registry company + Maestro registry model.

For the canonical surgical cluster context, see the surgical robotics cluster. For the replacement-robotics market-leader contrast, see what is Intuitive Surgical da Vinci. For the international commercial soft-tissue archetype contrast, see what is CMR Versius. For the canonical category umbrella, see what is physical AI. For methodology canonical references applicable to Moon Maestro: the 4-way autonomy-boundary taxonomy (CANONICAL assistive co-pilot tier worked example: only shipped assistive co-pilot in the cohort) + the 9-tier source-quality rubric (FDA K240598 + ScoPilot PCCP + Moon Surgical IR source classification).

Source: DEPLOY registry + surgical cluster framework + Moon Surgical company communications + FDA clearance database verification. Surgical cohort architecture + FDA-clearance-posture + commercial-model framework.
Entity	Surgical positioning	FDA-clearance posture	Cohort archetype
Moon Surgical Maestro	ASSISTIVE laparoscopy co-pilot (NOT replacement)	FDA 510(k) K240598 cleared Jun 2024 (verified-shipped)	Assistive-laparoscopy commercial-niche
Intuitive Surgical da Vinci	Replacement-robotics monolithic console	Cleared multi-procedure; 11,395 da Vinci + 1,041 Ion installed	Market-leader installed-base anchor
Johnson & Johnson Ottava	Replacement-robotics soft-tissue platform	De Novo submission Jan 2026; 'not authorized to be marketed'	Pre-market research-tier (corporate-scale)
CMR Versius	Replacement-robotics modular soft-tissue	US clearance state cap-flagged pending primary-source	International commercial soft-tissue

Frequently asked questions

What is Moon Surgical Maestro?: Moon Surgical Maestro is the Maestro Laparoscopy Co-Pilot, an FDA-cleared ASSISTIVE (NOT replacement) robotic system for laparoscopic procedures from Moon Surgical, a French-US dual-base company founded 2020. Per DEPLOY's surgical cluster framework, Maestro anchors the assistive-laparoscopy commercial-niche archetype within the surgical cluster: FDA 510(k) K240598 cleared June 2024 (primary-source FDA database verified); smaller-footprint OR integration; commercial-niche positioning distinct from replacement-robotics dominant cluster positioning.
Is Maestro a surgical robot or a co-pilot?: Maestro is an ASSISTIVE laparoscopy co-pilot, NOT a replacement surgical robot per DEPLOY's surgical cluster framework. Maestro (assistive): augments surgeons within existing laparoscopic procedures; co-pilot integration with laparoscopic instrument manipulation; does NOT replace the surgeon's primary laparoscopic technique. Replacement-robotics (Intuitive da Vinci, CMR Versius, Medtronic Hugo, J&J Ottava): replaces direct-manipulation laparoscopy with teleoperated console-driven robotic surgery. Per DEPLOY's framework, the assistive-vs-replacement distinction is the load-bearing editorial throughline at the surgical-cluster commercial-model variance layer.
Is Moon Surgical Maestro FDA-cleared?: Yes, FDA 510(k) K240598 cleared June 2024 per primary-source FDA database verification. Both K-number + clearance date operate at primary-source-anchored verification tier. Editorial-transparency: this anchor previously framed clearance as "December 2023 (specific K-number at cap-flag pending primary-source confirmation)"; primary-source FDA database research surfaces K240598 cleared June 2024 (corrected June 4, 2026 per Project C Anchor 2 framework-in-action narrative). The verified gating-event places Maestro at the verified-commercial-shipped tier within the cohort, distinct from US-pre-market surgical entrants (J&J Ottava De Novo submission January 2026 + Vicarious Surgical V1 SPAC-era distressed pre-market).
Who founded Moon Surgical?: Moon Surgical was founded in 2020 as a French-US dual-base surgical robotics company per DEPLOY's surgical cluster framework. The French + US dual-headquartered structure positions Moon within the international + US surgical robotics industrial base layers; the founding cohort + leadership operates across French + US surgical-technology development infrastructure. Per DEPLOY's surgical cluster framework, Moon's international + US dual positioning extends the surgical cluster's geographic-industrial-base coverage beyond US-only headquarters.
What's the difference between Maestro and da Vinci?: Surgical positioning. Maestro (assistive): augments surgeons within existing laparoscopic procedures; co-pilot integration with laparoscopic instrument manipulation; smaller-footprint OR integration; does NOT replace the surgeon's primary laparoscopic technique; FDA 510(k) K240598 cleared June 2024. Intuitive da Vinci (replacement-robotics): replaces direct-manipulation laparoscopy with teleoperated console-driven robotic surgery; surgeon at console drives the robotic arms; 11,395 da Vinci + 1,041 Ion systems installed-base. Per DEPLOY's surgical cluster framework, Maestro anchors the assistive-laparoscopy commercial-niche archetype; da Vinci anchors the market-leader installed-base replacement-robotics archetype.
How much does Moon Surgical Maestro cost?: Consumer-surface pricing forthcoming via Agent B's parallel surgical /price expansion per DEPLOY's surgical cluster framework. The /price page operates at honest-absence pending Agent B's parallel ship per cap-flag-as-trust-signal. Per DEPLOY's framework, surgical-platform pricing operates at hospital-system + surgical-services-network procurement tier rather than consumer retail; aggregator-quoted unit pricing without Moon Surgical primary-source confirmation operates outside DEPLOY's verification posture. Registry institutional depth available at Moon Surgical registry company + Maestro registry model.

Moon Surgical Maestro verified as assistive-laparoscopy commercial-niche archetype. Moon Surgical French-US dual base; founded 2020. Maestro Laparoscopy Co-Pilot FDA 510(k) K240598 cleared June 2024 (primary-source FDA database verified; K-number + clearance date both primary-source-anchored). Editorial-transparency: anchor previously framed clearance as December 2023 (specific K-number at cap-flag pending primary-source confirmation); primary-source FDA database research surfaces K240598 cleared June 2024 (corrected June 4, 2026 per Project C Anchor 2 framework-in-action narrative). CRITICAL EDITORIAL DISTINCTION: ASSISTIVE (NOT replacement) positioning; augments surgeons within existing laparoscopic procedures rather than replacing direct-manipulation laparoscopy as full surgical platforms (Intuitive da Vinci, CMR Versius, Medtronic Hugo, J&J Ottava). Smaller-footprint OR integration; commercial-niche positioning distinct from replacement-robotics dominant cluster positioning. Moon Surgical operates as the cohort's autonomy-spectrum-genuine shipped surgical AI standout (ScoPilot autonomous-registration with Predetermined Change Control Plan); Maestro extends verified-shipped assistive-AI positioning into laparoscopy co-pilot scope. Wave 2 expansion structural point: extends surgical cluster from FDA-clearance-posture (Wave 1) into clinical-domain + commercial-model variance. How DEPLOY verifies →

Compare alternatives

Moon Surgical registry companyMoon Maestro registry modelCMR Versius comparison explainerSurgical robotics cluster

More in surgical robotics

View all 18 explainers in surgical robotics →

← All explainers

What is Moon Surgical Maestro?

Moon Surgical Maestro: assistive-laparoscopy commercial-niche archetype

Moon Surgical: French-US dual base, founded 2020

FDA 510(k) K240598 cleared June 2024

CRITICAL EDITORIAL DISTINCTION: ASSISTIVE (NOT replacement)

Smaller-footprint OR integration

Cohort's genuine shipped assistive-AI exemplar

Cohort positioning: assistive-laparoscopy commercial-niche archetype

Frequently asked questions

Continue reading

What is Intuitive Surgical da Vinci?

What is CMR Versius?

What is Johnson & Johnson Ottava?

The surgical robotics cluster

More in surgical robotics